Trial intelligence / Profile preview

Efficacy of Rituximab in rheumatoid arthritis patients with inadequate response to TNF blockers

2006-004673-98Phase 4Completed

Sponsor
Roche
Start
Sep 2006
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

Phase 4 trial of rituximab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoints: DAS28 Assessments and ACR20/50/70 response. Started Sep 2006; status: completed.

02

Drugs

rituximab
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on 2006-004673-98.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-004673-98.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call